Marshall Wace North America’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-108,585
| Closed | -$18.4M | – | 1345 |
|
|
2021
Q2 | $18.4M | Buy |
+108,585
| New | +$18.4M | 0.08% | 267 |
|
|
2021
Q1 | – | Sell |
-150,004
| Closed | -$19.5M | – | 1442 |
|
|
2020
Q4 | $19.5M | Sell |
150,004
-92,656
| -38% | -$12M | 0.09% | 258 |
|
|
2020
Q3 | $35.3M | Sell |
242,660
-69,179
| -22% | -$10.1M | 0.23% | 117 |
|
|
2020
Q2 | $46.2M | Buy |
311,839
+19,090
| +7% | +$2.83M | 0.31% | 86 |
|
|
2020
Q1 | $31.9M | Buy |
292,749
+125,891
| +75% | +$13.7M | 0.24% | 117 |
|
|
2019
Q4 | $19.2M | Buy |
+166,858
| New | +$19.2M | 0.09% | 206 |
|
|
2019
Q3 | – | Sell |
-181,395
| Closed | -$13.2M | – | 1295 |
|
|
2019
Q2 | $13.2M | Buy |
+181,395
| New | +$13.2M | 0.08% | 206 |
|
|
2018
Q3 | – | Sell |
-26,553
| Closed | -$2.62M | – | 901 |
|
|
2018
Q2 | $2.62M | Buy |
+26,553
| New | +$2.62M | 0.01% | 694 |
|
|
2017
Q2 | – | Sell |
-8,767
| Closed | -$447K | – | 1276 |
|
|
2017
Q1 | $447K | Buy |
+8,767
| New | +$447K | ﹤0.01% | 829 |
|
|
2013
Q3 | – | Sell |
-87,828
| Closed | -$2.72M | – | 607 |
|
|
2013
Q2 | $2.72M | Buy |
+87,828
| New | +$2.72M | 0.21% | 147 |
|